KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Payables: 2009-2024

Historic Payables for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $88.4 million.

  • Alnylam Pharmaceuticals' Payables rose 66.08% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.8 million, marking a year-over-year increase of 45.73%. This contributed to the annual value of $88.4 million for FY2024, which is 59.25% up from last year.
  • Alnylam Pharmaceuticals' Payables amounted to $88.4 million in FY2024, which was up 59.25% from $55.5 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Payables' 5-year high stood at $98.1 million during FY2022, with a 5-year trough of $52.0 million in FY2020.
  • Moreover, its 3-year median value for Payables was $88.4 million (2024), whereas its average is $80.7 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Payables plummeted by 43.40% in 2023, and later skyrocketed by 59.25% in 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' Payables (Yearly) stood at $52.0 million in 2020, then surged by 41.30% to $73.4 million in 2021, then surged by 33.60% to $98.1 million in 2022, then tumbled by 43.40% to $55.5 million in 2023, then soared by 59.25% to $88.4 million in 2024.